miR‐451a inhibits cancer growth, epithelial‐mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8

• Published in: Journal of cellular and molecular medicine Vol. 23; no. 12; pp. 8067 - 8075
• Main Authors: Fan, Xinlong, Zhao, Yuejiao
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-12-2019; John Wiley and Sons Inc
• Subjects: Animals; Apoptosis; Apoptosis - genetics; Biomarkers; Cell growth; Cell Line, Tumor; Cell Movement - genetics; Cell proliferation; Cell Proliferation - genetics; Disease Progression; Epithelial-Mesenchymal Transition - genetics; Ethics; Experiments; Gene Expression Regulation, Neoplastic - genetics; Humans; Lung cancer; Lymphatic system; Medical prognosis; Mesenchyme; Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; miRNAs; miR‐451a; Original; Papillary thyroid cancer; Proteasome Endopeptidase Complex - genetics; Proteasome Endopeptidase Complex - metabolism; Proteasomes; Proteins; PSMB8; RNA, Small Interfering; Studies; Thyroid cancer; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - metabolism; Transplantation, Heterologous; Tumor cell lines; miRNAs; miR-451a; papillary thyroid cancer; PSMB8
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.14673

Despite the increasing incidence of papillary thyroid cancer in the past decade, the molecular mechanism underlying its progression remains unknown. Several studies have reported down‐regulation of miR‐451a or circular miR‐451a in papillary thyroid cancer cell lines or patients. However, the underlying molecular mechanism remains unknown. In this study, we found that overexpression of miR‐451a could inhibit proliferation, epithelial‐mesenchymal transition and induce apoptosis in papillary thyroid cancer cells. Proteasome subunit beta type‐8 was predicted to be a direct target of miR‐451a and was validated with a luciferase reporter assay. Further functional assays showed that miR‐451a could inhibit thyroid cancer progression by targeting proteasome subunit beta type‐8.